CAFC Unsure about AstraZeneca’s Patent Validity Ruling by Lower Court

shot by IP News Shots / 7:05 pm on 01 September, 2021

The US Court of Appeals for the Federal Circuit (CAFC) seems unsure of a lower court’s decision upholding three of AstraZeneca PLC’s patents for Symbicort. The court is leaning towards accepting Mylan N.V.’s argument that the lower court erred during claim construction for the inhaler asthma treatment patents as they were too broad.

Industry: Pharmaceuticals | Type of IP: Litigations

Read more at Law360